The Importance of Determining the Drug Agent Responsible for Pancytopenia in Patients with Rheumatoid Arthritis and Additional Systemic Diseases

Creative Commons License

ÜSKÜDAR TEKE H., Tasdemir A. E., Ozen M.

TURKISH JOURNAL OF RHEUMATOLOGY, vol.28, no.2, pp.123-127, 2013 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 2
  • Publication Date: 2013
  • Doi Number: 10.5606/tjr.2013.2808
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.123-127
  • Eskisehir Osmangazi University Affiliated: Yes


Methotrexate (MTX) is the most commonly used drug in the treatment of rheumatoid arthritis (RA). In MTX-treated RA patients, the prevalence of pancytopenia is nearly 3%. Several medications may be prescribed for RA patients with an additional systemic disease. This may result in bone marrow toxicity, making it difficult to know which drug induced the pancytopenic condition. Therefore, identifying the culprit agent through bone marrow aspiration and biopsy findings of the samples is critical for determining the best course of treatment for pancytopenia. Significantly increased amounts of eosinophilia in the bone marrow indicate that MTX is the culprit for the presentation of pancytopenia.